Findings

What do systematic reviews say?

15 questions · 17 findings · 3 reviews · Breast Cancer

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 2 · 11.8%Moderate 2 · 11.8%High 13 · 76.5%

Platinum‐containing chemotherapy vs chemotherapy without platinum

OS at 2 years · neoadjuvant therapy for early triple‐negative breast cancer

Platinum‐containing chemotherapy leads to lower OS at 2 years compared with chemotherapy without platinum (high certainty).

1 finding from 1 review

Platinum‐based chemotherapy for early triple‐negative breast cancer 2023 · Cochrane Headline outcomes only
HR 0.69 [0.55, 0.86]
8 studies · 1973 participants
High

Platinum‐containing chemotherapy vs chemotherapy without platinum

OS at 5 years · neoadjuvant therapy for early triple‐negative breast cancer

Platinum‐containing chemotherapy leads to lower OS at 5 years compared with chemotherapy without platinum (high certainty).

1 finding from 1 review

Platinum‐based chemotherapy for early triple‐negative breast cancer 2023 · Cochrane Headline outcomes only
HR 0.69 [0.55, 0.86]
8 studies · 1973 participants
High

Platinum‐containing chemotherapy vs chemotherapy without platinum

OS at 2 years · early triple‐negative breast cancer

Platinum‐containing chemotherapy leads to lower OS at 2 years compared with chemotherapy without platinum (high certainty).

1 finding from 1 review

Platinum‐based chemotherapy for early triple‐negative breast cancer 2023 · Cochrane Headline outcomes only
HR 0.7 [0.5, 0.96]
4 studies · 1256 participants
High

Platinum‐containing chemotherapy vs chemotherapy without platinum

OS at 5 years · early triple‐negative breast cancer

Platinum‐containing chemotherapy leads to lower OS at 5 years compared with chemotherapy without platinum (high certainty).

1 finding from 1 review

Platinum‐based chemotherapy for early triple‐negative breast cancer 2023 · Cochrane Headline outcomes only
HR 0.7 [0.5, 0.96]
4 studies · 1256 participants
High

Platinum‐containing chemotherapy vs chemotherapy without platinum

Disease-free survival · neoadjuvant therapy for early triple‐negative breast cancer

Platinum‐containing chemotherapy leads to lower DFS at 2 years compared with chemotherapy without platinum (high certainty).

2 findings from 1 review

Platinum‐based chemotherapy for early triple‐negative breast cancer 2023 · Cochrane Headline outcomes only
HR 0.63 [0.53, 0.75]
8 studies · 1966 participants
High
Platinum‐based chemotherapy for early triple‐negative breast cancer 2023 · Cochrane Headline outcomes only
HR 0.63 [0.53, 0.75]
8 studies · 1966 participants
High

Platinum‐containing chemotherapy vs chemotherapy without platinum

Disease-free survival · early triple‐negative breast cancer

Platinum‐containing chemotherapy leads to lower DFS at 2 years compared with chemotherapy without platinum (high certainty).

2 findings from 1 review

Platinum‐based chemotherapy for early triple‐negative breast cancer 2023 · Cochrane Headline outcomes only
HR 0.69 [0.54, 0.88]
4 studies · 1256 participants
High
Platinum‐based chemotherapy for early triple‐negative breast cancer 2023 · Cochrane Headline outcomes only
HR 0.69 [0.54, 0.88]
4 studies · 1256 participants
High

Hypofractionated radiation therapy vs conventionally fractionated radiation therapy

Mortality at 10 years · women treated with breast conserving therapy for early breast cancer

Hypofractionated radiation therapy showed no clear difference in mortality at 10 years compared with conventionally fractionated radiation therapy (high certainty).

1 finding from 1 review

Hypofractionated radiation therapy for early breast cancer 2016 · Cochrane Headline outcomes only
HR 0.91 [0.8, 1.03]
3 studies · 5685 participants
High

Hypofractionated radiation therapy vs conventionally fractionated radiation therapy

Proportion of participants with relapse‐free survival at ≥ 12 months · women treated with breast conserving therapy for early breast cancer

Hypofractionated radiation therapy showed no clear difference in relapse‐free survival (RFS) at 10 years compared with conventionally fractionated radiation therapy (moderate certainty).

1 finding from 1 review

Hypofractionated radiation therapy for early breast cancer 2016 · Cochrane Headline outcomes only
HR 0.93 [0.82, 1.05]
3 studies · 5685 participants
Moderate

Hypofractionated radiation therapy vs conventionally fractionated radiation therapy

Local recurrence‐free survival · women treated with breast conserving therapy for early breast cancer

Hypofractionated radiation therapy showed no clear difference in local recurrence‐free survival (LR‐FS) at 10 years compared with conventionally fractionated radiation therapy (high certainty).

1 finding from 1 review

Hypofractionated radiation therapy for early breast cancer 2016 · Cochrane Headline outcomes only
HR 0.94 [0.77, 1.15]
4 studies · 7095 participants
High

Hypofractionated radiation therapy vs conventionally fractionated radiation therapy

Breast cancer‐specific survival · women treated with breast conserving therapy for early breast cancer

Hypofractionated radiation therapy showed no clear difference in breast cancer‐specific survival (BC‐SS) at 10 years compared with conventionally fractionated radiation therapy (high certainty).

1 finding from 1 review

Hypofractionated radiation therapy for early breast cancer 2016 · Cochrane Headline outcomes only
HR 0.91 [0.78, 1.06]
3 studies · 5685 participants
High

Boost vs no boost

Local recurrence · breast‐conserving radiotherapy for breast cancer

Boost may leads to lower local control: recurrence at 5 years compared with no boost (low certainty).

1 finding from 1 review

Tumour bed boost radiotherapy for women after breast‐conserving surgery 2017 · Cochrane Headline outcomes only
HR 0.64 [0.55, 0.75]
5 studies · 8315 participants
Low

Boost vs no boost

Overall survival: mortality at 5 years · breast‐conserving radiotherapy for breast cancer

Boost showed no clear difference in overall survival: mortality at 5 years compared with no boost (moderate certainty).

1 finding from 1 review

Tumour bed boost radiotherapy for women after breast‐conserving surgery 2017 · Cochrane Headline outcomes only
HR 1.04 [0.94, 1.14]
2 studies · 6342 participants
Moderate

Boost vs no boost

Sensitivity analysis: local control ‐ recurrence at 5 years · breast‐conserving radiotherapy for breast cancer

Boost leads to lower sensitivity analysis: local control ‐ recurrence at 5 years compared with no boost (high certainty).

1 finding from 1 review

Tumour bed boost radiotherapy for women after breast‐conserving surgery 2017 · Cochrane Headline outcomes only
HR 0.62 [0.52, 0.73]
3 studies · 6963 participants
High

Boost vs no boost

Disease-free survival (new disease, progression or mortality) · breast‐conserving radiotherapy for breast cancer

Boost showed no clear difference in disease‐free survival: disease progression/mortality at 5 years compared with no boost (low certainty).

1 finding from 1 review

Tumour bed boost radiotherapy for women after breast‐conserving surgery 2017 · Cochrane Headline outcomes only
HR 0.94 [0.87, 1.02]
3 studies · 6549 participants
Low

Boost vs no boost

Subgroup analysis: local control ‐ > 40 years old, recurrence at 5 years · breast‐conserving radiotherapy for breast cancer

Boost leads to lower subgroup analysis: local control ‐ > 40 years old, recurrence at 5… compared with no boost (high certainty).

1 finding from 1 review

Tumour bed boost radiotherapy for women after breast‐conserving surgery 2017 · Cochrane Headline outcomes only
HR 0.65 [0.53, 0.81]
2 studies · 5058 participants
High